Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy

Allen Yeilding, Luigi Bertoli, Peter Eisenberg, Patricia Plezia, Manuel R. Modiano, David S Alberts, Ali Khojasteh, Michael B. Cramer, William F. Hahne

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This randomized, double-blind, parallel-group, multicenter study compared the antiemetic effectiveness, safety, and tolerability of two different intravenous (i.v.) doses of dolasetron mesylate (0.6 and 1.8 mg/kg) in cancer patients receiving their first course of high-dose cisplatin- containing chemotherapy (≤75 mg/m 2). Efficacy was assessed by recording the timing, number, and severity of emetic episodes in the 24 h following high- dose cisplatin. Safety was evaluated by monitoring adverse events, vital signs, clinical laboratory parameters, and electrocardiograms. Of the 62 patients enrolled in the study, 29 received 0.6 mg/kg of dolasetron mesylate and 33 received 1.8 mg/kg. Patients who received dolasetron mesylate 1.8 mg/kg consistently experienced a greater degree of antiemetic control than those who received 0.6 mg/kg. Complete responses were achieved by 55% of patients who received 1.8 mg/kg compared with 31% for the 0.6-mg/kg group. The 1.8-mg/kg group achieved a significantly (p = 0.039) higher complete/major response rate than the 0.6-mg/kg group (77% vs 55%, respectively) and a significantly (p = 0.004) longer time to the first emetic episode (>24 h vs 13.5 h, respectively). More than 80% of patients were either satisfied or very satisfied with dolasetron treatment. The most common adverse events were mild to moderate in intensity, consistent with other studies, and included headache (24.1% of patients) and diarrhea (4.8%). These results demonstrated that a single 1.8-mg/kg i.v. dose of dolasetron mesylate provided effective antiemetic activity in a majority of patients given high- dose cisplatin for the first time and should be evaluated further in clinical trials.

Original languageEnglish (US)
Pages (from-to)619-623
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number6
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Antiemetics
Cisplatin
Drug Therapy
Emetics
Safety
Vital Signs
dolasetron
Multicenter Studies
Headache
Diarrhea
Electrocardiography
Clinical Trials
Neoplasms

Keywords

  • 5- HT
  • antagonist
  • Antiemetic
  • Chemotherapy-induced emesis
  • Cisplatin
  • Clinical trial
  • Dolasetron
  • Emesis
  • Nausea

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. / Yeilding, Allen; Bertoli, Luigi; Eisenberg, Peter; Plezia, Patricia; Modiano, Manuel R.; Alberts, David S; Khojasteh, Ali; Cramer, Michael B.; Hahne, William F.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 19, No. 6, 1996, p. 619-623.

Research output: Contribution to journalArticle

Yeilding, Allen ; Bertoli, Luigi ; Eisenberg, Peter ; Plezia, Patricia ; Modiano, Manuel R. ; Alberts, David S ; Khojasteh, Ali ; Cramer, Michael B. ; Hahne, William F. / Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1996 ; Vol. 19, No. 6. pp. 619-623.
@article{c5c91326ecb94dd79198287c6b672639,
title = "Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy",
abstract = "This randomized, double-blind, parallel-group, multicenter study compared the antiemetic effectiveness, safety, and tolerability of two different intravenous (i.v.) doses of dolasetron mesylate (0.6 and 1.8 mg/kg) in cancer patients receiving their first course of high-dose cisplatin- containing chemotherapy (≤75 mg/m 2). Efficacy was assessed by recording the timing, number, and severity of emetic episodes in the 24 h following high- dose cisplatin. Safety was evaluated by monitoring adverse events, vital signs, clinical laboratory parameters, and electrocardiograms. Of the 62 patients enrolled in the study, 29 received 0.6 mg/kg of dolasetron mesylate and 33 received 1.8 mg/kg. Patients who received dolasetron mesylate 1.8 mg/kg consistently experienced a greater degree of antiemetic control than those who received 0.6 mg/kg. Complete responses were achieved by 55{\%} of patients who received 1.8 mg/kg compared with 31{\%} for the 0.6-mg/kg group. The 1.8-mg/kg group achieved a significantly (p = 0.039) higher complete/major response rate than the 0.6-mg/kg group (77{\%} vs 55{\%}, respectively) and a significantly (p = 0.004) longer time to the first emetic episode (>24 h vs 13.5 h, respectively). More than 80{\%} of patients were either satisfied or very satisfied with dolasetron treatment. The most common adverse events were mild to moderate in intensity, consistent with other studies, and included headache (24.1{\%} of patients) and diarrhea (4.8{\%}). These results demonstrated that a single 1.8-mg/kg i.v. dose of dolasetron mesylate provided effective antiemetic activity in a majority of patients given high- dose cisplatin for the first time and should be evaluated further in clinical trials.",
keywords = "5- HT, antagonist, Antiemetic, Chemotherapy-induced emesis, Cisplatin, Clinical trial, Dolasetron, Emesis, Nausea",
author = "Allen Yeilding and Luigi Bertoli and Peter Eisenberg and Patricia Plezia and Modiano, {Manuel R.} and Alberts, {David S} and Ali Khojasteh and Cramer, {Michael B.} and Hahne, {William F.}",
year = "1996",
doi = "10.1097/00000421-199612000-00018",
language = "English (US)",
volume = "19",
pages = "619--623",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy

AU - Yeilding, Allen

AU - Bertoli, Luigi

AU - Eisenberg, Peter

AU - Plezia, Patricia

AU - Modiano, Manuel R.

AU - Alberts, David S

AU - Khojasteh, Ali

AU - Cramer, Michael B.

AU - Hahne, William F.

PY - 1996

Y1 - 1996

N2 - This randomized, double-blind, parallel-group, multicenter study compared the antiemetic effectiveness, safety, and tolerability of two different intravenous (i.v.) doses of dolasetron mesylate (0.6 and 1.8 mg/kg) in cancer patients receiving their first course of high-dose cisplatin- containing chemotherapy (≤75 mg/m 2). Efficacy was assessed by recording the timing, number, and severity of emetic episodes in the 24 h following high- dose cisplatin. Safety was evaluated by monitoring adverse events, vital signs, clinical laboratory parameters, and electrocardiograms. Of the 62 patients enrolled in the study, 29 received 0.6 mg/kg of dolasetron mesylate and 33 received 1.8 mg/kg. Patients who received dolasetron mesylate 1.8 mg/kg consistently experienced a greater degree of antiemetic control than those who received 0.6 mg/kg. Complete responses were achieved by 55% of patients who received 1.8 mg/kg compared with 31% for the 0.6-mg/kg group. The 1.8-mg/kg group achieved a significantly (p = 0.039) higher complete/major response rate than the 0.6-mg/kg group (77% vs 55%, respectively) and a significantly (p = 0.004) longer time to the first emetic episode (>24 h vs 13.5 h, respectively). More than 80% of patients were either satisfied or very satisfied with dolasetron treatment. The most common adverse events were mild to moderate in intensity, consistent with other studies, and included headache (24.1% of patients) and diarrhea (4.8%). These results demonstrated that a single 1.8-mg/kg i.v. dose of dolasetron mesylate provided effective antiemetic activity in a majority of patients given high- dose cisplatin for the first time and should be evaluated further in clinical trials.

AB - This randomized, double-blind, parallel-group, multicenter study compared the antiemetic effectiveness, safety, and tolerability of two different intravenous (i.v.) doses of dolasetron mesylate (0.6 and 1.8 mg/kg) in cancer patients receiving their first course of high-dose cisplatin- containing chemotherapy (≤75 mg/m 2). Efficacy was assessed by recording the timing, number, and severity of emetic episodes in the 24 h following high- dose cisplatin. Safety was evaluated by monitoring adverse events, vital signs, clinical laboratory parameters, and electrocardiograms. Of the 62 patients enrolled in the study, 29 received 0.6 mg/kg of dolasetron mesylate and 33 received 1.8 mg/kg. Patients who received dolasetron mesylate 1.8 mg/kg consistently experienced a greater degree of antiemetic control than those who received 0.6 mg/kg. Complete responses were achieved by 55% of patients who received 1.8 mg/kg compared with 31% for the 0.6-mg/kg group. The 1.8-mg/kg group achieved a significantly (p = 0.039) higher complete/major response rate than the 0.6-mg/kg group (77% vs 55%, respectively) and a significantly (p = 0.004) longer time to the first emetic episode (>24 h vs 13.5 h, respectively). More than 80% of patients were either satisfied or very satisfied with dolasetron treatment. The most common adverse events were mild to moderate in intensity, consistent with other studies, and included headache (24.1% of patients) and diarrhea (4.8%). These results demonstrated that a single 1.8-mg/kg i.v. dose of dolasetron mesylate provided effective antiemetic activity in a majority of patients given high- dose cisplatin for the first time and should be evaluated further in clinical trials.

KW - 5- HT

KW - antagonist

KW - Antiemetic

KW - Chemotherapy-induced emesis

KW - Cisplatin

KW - Clinical trial

KW - Dolasetron

KW - Emesis

KW - Nausea

UR - http://www.scopus.com/inward/record.url?scp=0029852564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029852564&partnerID=8YFLogxK

U2 - 10.1097/00000421-199612000-00018

DO - 10.1097/00000421-199612000-00018

M3 - Article

C2 - 8931684

AN - SCOPUS:0029852564

VL - 19

SP - 619

EP - 623

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -